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THE EFFECT OF CELECOXIB ON PAIN AND PHYSICAL 
FUNCTION IN KNEE OSTEOARTHRITIS PATIENTS 
TP Stitik, DM Stiskal, JH Kim, L Schoenherr, N Shenoy, M Coba 
Physical Medicine and Rehabilitation, UMDNJ- New Jersey 
Medical School, Newark, NJ 
Introduction: A Cox-II inhibitor such as celecoxib (Celebrex) is 
one of the recommended pharmacologic treatments for medical 
management of knee osteoarthritis (OA). Few studies exist that 
examine the relationship between Cox-II inhibitor use and out- 
come measures such as quadriceps strength, pain and function 
in patients with knee OA. The aim of this pilot study was to assess 
the effectiveness of celecoxib in improving quadriceps strength, 
function and knee pain. 
Methods: Using a multiple baseline, within-subjects repeated 
measures design; we recruited six subjects who met inclusion 
criteria that are consistent with the American College of Rheuma- 
tology Guidelines for the diagnosis of knee OA. All subjects were 
evaluated for 3 baseline visits at 2 week intervals to capture 
an accurate measure of their pre-medication status. At the third 
baseline visit, subjects were then given a six week course of 
celecoxib (200 mg/d).Outcome measures continued to be col- 
lected at 2 week intervals during the 6 week course of medi- 
cation. Dependant variables included WOMAC (Western Ontario 
and McMaster Universities Osteoarthritis Index) pain, stiffness 
and function scales; left and right quadriceps isometric strength; 
and the "Timed Get Up and Go Test" (TUG). A repeated mea- 
sures ANOVA was employed to determine differences from base- 
line measures. 
Results: The mean of the three baseline measures were aver- 
aged and this value was then used to compare with scores ob- 
tained at 2, 4, and 6 weeks during the course of medication. Sig- 
nificant reductions in pain (F = 17.83, p <.000), stiffness (F = 
33.76, p <.000) and function (F = 22.28, p <.000) were found. 
Post-hoc analyses revealed each of the four measures differed 
significantly from the other three for pain (p = 0.05), stiffness (p 
= 0.01) and function (p = 0.03). Both right and left quadriceps 
strength scores significantly increased (F = 3.60, p = 0.04 and F= 
5.12, p = 0.01, respectively). Furthermore, participants reduced 
their time needed to complete the TUG (F = 4.67, p = 0.02). 
Conclusions: Our results showed that subjects improved in all 
aspects of self reported pain, stiffness and function. In addition 
to perceived benefits, subjects also had significant improvements 
in quadriceps trength and locomotor performance during the six 
week course of celecoxib. 
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As part of a larger study of five supplements and placebo, ex- 
ploratory comparisons of changes in symptoms of subjects with 
knee osteoarthritis between specific groups were performed. 
Eighteen subjects per group took either 1500 mg Glucosamine 
HCI (G) or a proprietary formula (1500 mg Glucosamine HCI, 250 
mg Uniflex herbal extract, 3.3 mg Sodium Hyaluronate, PF) daily 
in twelve capsules for eight weeks. PF was given in a loading 
dose of double the usual amount for the first two weeks. Uni- 
flex herbal extact consisted of a proprietary extract of Scutellaria 
baicalensis (Chinese Scullcap) and Acacia catechu (Black Cat- 
echu), with bioflavonoids baicalein and catechin as major com- 
ponents. Molecular weight of sodium hyaluronate was approxi- 
mately one million daltons. WOMAC, SF-36v2, Brief Pain Inven- 
tory and Pain Relief Diary outcomes were measured at 0, 1,2, 4, 
1 nd 8 weeks. After a one-way ANOVA (using intent-to-treat data) 
on all six groups indicated the presence of significant between- 
group differences, post-hoc comparisons of the changes from 
baseline between the G and PF groups were performed by Stu- 
dent t, Mann-Whitney U, and Fisher Exact tests. 
There were three dropouts in the G and four in the PF group. Af- 
ter one week, significant changes from baseline for efficacy mea- 
surements occurred more frequently in the PF group (16/26) than 
in the G group (3/26) (P=0.0004). PF group was significantly im- 
proved over G group at one week for SF-36v2 Physical Function 
(P=0.051) and Role Physical (P=0.049) scores. After eight weeks, 
100% of PF and 80% of G subjects reported decreased joint 
pain (by WOMAC Pain subscale and Pain Relief Diary). WOMAC 
Total scores were reduced 46% and 34% from baseline for PF 
and G groups, respectively after eight weeks (P=0.471). SF-36v2 
Physical Component Scores were improved 32% greater in the 
PF group (P=0.434). For all measurements and time points, the 
average difference between G and PF groups was 1.93x when 
PF group values were improved compared to G group values 
(P=0.014 by log-transformed t test). 
It may be tentatively concluded that the addition of an herbal ex- 
tract and hyaluronate to glucosamine led to faster and larger im- 
provements in parameters of joint health and quality of life over 
an eight week period. 
P195 
COMPARISON BETWEEN GLUCOSAMINE WITH 
CHONDROITIN AND A PROPRIETARY DIETARY 
SUPPLEMENT FOR SYMPTOMS OF KNEE 
OSTEOARTHRITIS 
LR Bucci 1 , E Sheldon 2, H Schwartz 2, J Pahcon 2, D Kalman 2, M 
Mederos 2, JC Pezzullo 2, C Beer 1 
1Research, Schiff Nutrition International, Salt Lake Citj4, UT; 
2primary Research Office, Miami Research Associates, Miami, 
FL 
As part of a larger study of five supplements and placebo, ex- 
ploratory comparisons of changes in symptoms of subjects with 
knee osteoarthritis between specific product groups were per- 
formed. Eighteen subjects per group took either 1500 mg Glu- 
cosamine HCI and 1200 mg Chondroitin Sulfates (GC) or a pro- 
prietary formula (1500 mg Glucosamine HCI, 250 mg Uniflex 
herbal extract, 3.3 mg Sodium Hyaluronate, PF) in twelve cap- 
sules daily for eight weeks. PF was given in a loading dose of dou- 
ble the usual amount for the first two weeks. Herbal extract con- 
sisted of a proprietary extract of Scutellaria baicalensis (Chinese 
Scullcap) and Acacia catechu (Black Catechu), with bioflavonoids 
baicalein and catechin as major components. Molecular weight 
of sodium hyaluronate was approximately one million daltons. 
WOMAC, SF-36v2, Brief Pain Inventory and Pain Relief Diary 
outcomes were measured at 0, 1,2, 4, and 8 weeks. After a one- 
way ANOVA (using intent-to-treat data) on all six groups indicated 
the presence of significant between-group differences, post-hoc 
comparisons of the changes from baseline between the GC and 
PF groups were performed by Student t, Mann-Whitney U, and 
Fisher Exact tests. 
There were four dropouts in the GC and four in the PF group. After 
one week, significant changes from baseline in efficacy measure- 
ments were found more frequently than in the PF group (16/26) 
than in the GC group (6/26) (P=0.011 by Fisher Exact test). 
After eight weeks, PF group showed larger improvements than 
GC group for WOMAC Total scores (P=0.027), Pain Relief Diary 
